The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
Condition(s):Ovarian Cancer; Clinical Marker; PARP InhibitorLast Updated:January 20, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Ovarian Cancer; Clinical Marker; PARP InhibitorLast Updated:January 20, 2021Unknown status
Condition(s):Lung CancerLast Updated:May 26, 2022Recruiting
Condition(s):Ovarian Cancer RecurrentLast Updated:June 7, 2023Withdrawn
Condition(s):Metastatic Breast CancerLast Updated:July 20, 2023Active, not recruiting
Condition(s):Ovarian CancerLast Updated:March 14, 2023Active, not recruiting
Condition(s):Ovarian NeoplasmsLast Updated:February 5, 2024Not yet recruiting
Condition(s):Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorLast Updated:July 12, 2021Recruiting
Condition(s):CancerLast Updated:September 23, 2021Completed
Condition(s):PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum RetreatmentLast Updated:May 24, 2023Recruiting
Condition(s):CancerLast Updated:March 11, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.